Summary
The post-acute phase (PAP) of COVID-19, occurring ≥4 months after the acute phase, is associated with an increased risk for the development of non-communicable diseases (NCDs). The risk of complications in this phase does not depend on the severity of the acute phase. In the EU, more than 183 million cases of COVID-19 have been reported and up to 70% of patients suffer reduced organ function in the PAP. Our conservative estimate it that 5% of people who have suffered COVID-19 are at risk of developing NCDs of the pulmonary, cardiovascular and renal systems due to the PAP.
To avoid the significant socioeconomic costs related to this burden, POINT will develop knowledge-based biomarkers for prevention and management of NCDs, a virtual twin model that offers clinical decision support, and clinical guidelines and recommendations for the entire health care value chain with special attention to vulnerable groups. We will fulfil an unmet need for knowledge and tools to minimize the risk factors of the PAP at the optimal point in time, when healthcare systems will have to redirect their focus from the acute phase of COVID-19 to the post-acute phase. The outcomes of POINT will aid the health care value chain already from an early phase of the project. Furthermore, POINT will correlate and promote knowledge on the development of NCDs in general and the risks of PAP from other infectious diseases.
POINT will meet the challenges with a holistic approach from a truly interdisciplinary consortium consisting of clinical experts, molecular biologists, behavioural scientists, and computer scientists, who will take advantage of cohorts of more than 6 million Europeans, and cross-sectional biobanks from more than 6000 Europeans. Researchers will work together with standardisation experts, an end-user organization representing >120.000 physicians, as well as a dedicated partner for data management ensuring rapid absorption of the outcomes of the project by all stakeholders.
To avoid the significant socioeconomic costs related to this burden, POINT will develop knowledge-based biomarkers for prevention and management of NCDs, a virtual twin model that offers clinical decision support, and clinical guidelines and recommendations for the entire health care value chain with special attention to vulnerable groups. We will fulfil an unmet need for knowledge and tools to minimize the risk factors of the PAP at the optimal point in time, when healthcare systems will have to redirect their focus from the acute phase of COVID-19 to the post-acute phase. The outcomes of POINT will aid the health care value chain already from an early phase of the project. Furthermore, POINT will correlate and promote knowledge on the development of NCDs in general and the risks of PAP from other infectious diseases.
POINT will meet the challenges with a holistic approach from a truly interdisciplinary consortium consisting of clinical experts, molecular biologists, behavioural scientists, and computer scientists, who will take advantage of cohorts of more than 6 million Europeans, and cross-sectional biobanks from more than 6000 Europeans. Researchers will work together with standardisation experts, an end-user organization representing >120.000 physicians, as well as a dedicated partner for data management ensuring rapid absorption of the outcomes of the project by all stakeholders.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101137196 |
| Start date: | 01-01-2024 |
| End date: | 31-12-2027 |
| Total budget - Public funding: | 6 676 490,00 Euro - 6 676 490,00 Euro |
Cordis data
Original description
The post-acute phase (PAP) of COVID-19, occurring ≥4 months after the acute phase, is associated with an increased risk for the development of non-communicable diseases (NCDs). The risk of complications in this phase does not depend on the severity of the acute phase. In the EU, more than 183 million cases of COVID-19 have been reported and up to 70% of patients suffer reduced organ function in the PAP. Our conservative estimate it that 5% of people who have suffered COVID-19 are at risk of developing NCDs of the pulmonary, cardiovascular and renal systems due to the PAP.To avoid the significant socioeconomic costs related to this burden, POINT will develop knowledge-based biomarkers for prevention and management of NCDs, a virtual twin model that offers clinical decision support, and clinical guidelines and recommendations for the entire health care value chain with special attention to vulnerable groups. We will fulfil an unmet need for knowledge and tools to minimize the risk factors of the PAP at the optimal point in time, when healthcare systems will have to redirect their focus from the acute phase of COVID-19 to the post-acute phase. The outcomes of POINT will aid the health care value chain already from an early phase of the project. Furthermore, POINT will correlate and promote knowledge on the development of NCDs in general and the risks of PAP from other infectious diseases.
POINT will meet the challenges with a holistic approach from a truly interdisciplinary consortium consisting of clinical experts, molecular biologists, behavioural scientists, and computer scientists, who will take advantage of cohorts of more than 6 million Europeans, and cross-sectional biobanks from more than 6000 Europeans. Researchers will work together with standardisation experts, an end-user organization representing >120.000 physicians, as well as a dedicated partner for data management ensuring rapid absorption of the outcomes of the project by all stakeholders.
Status
SIGNEDCall topic
HORIZON-HLTH-2023-DISEASE-03-07Update Date
12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| KOBENHAVNS UNIVERSITET (Coördinator)
-
| BioFi AG
-
| DET KONGELIGE BIBLIOTEK, NATIONALBIBLIOTEK OG KOBENHAVNS UNIVERSITETSBIBLIOTEK
-
| DIN DEUTSCHES INSTITUT FUER NORMUNG E.V.
-
| ELLINIKO INSTITUTO MELETIS TIS SIPSIS
-
| FONDAZIONE ICONS
-
| KATHOLIEKE UNIVERSITEIT LEUVEN
-
| REGION HOVEDSTADEN
-
| STICHTING WONCA EUROPE
-
| TARTU ULIKOOL